In contrast to the hereditary form of medullary thyroid carcinoma (MTC), little is known about the etiology of sporadic MTC. Somatic gain-of-function mutations in the RET proto-oncogene, encoding a receptor tyrosine kinase, are found in an average of 40% of sporadic MTC. We analysed 31 sporadic MTC for somatic and germline variants in GFRA1, GFRA2 and GFRA3 which encode the co-receptors of RET. Although there were no somatic mutations in any of the three genes, a sequence variant (7193C4G) in the 5'-UTR of GFRA1 was found in 15% of cases. Three patients were heterozygous (het); another three patients homozygous (hom) for the G variant. The G allele was not observed in 31 racematched normal controls. Hence, the relative frequency of this variant in sporadic MTC cases and controls diered signi®cantly (P50.05). Since this variant lies in the 5' UTR, likely at the transcriptional start site, we analysed for dierential expression of GFRa-1 at the transcript and protein levels. At the mRNA level, GFRA1 was over-expressed in tumors harboring the rare variant (P=0.06). The presence of the G polymorphic allele seemed to be associated with increased expression by immunostaining for GFRa-1. Interestingly, cytoplasmic staining was stronger in intensity for het patients and nuclear staining predominant in hom cases.
Introduction
Medullary thyroid carcinoma (MTC) accounts for 5 ± 10% of all thyroid malignancies. About 25% are hereditary, the etiology of which is well known. Germline gain-of-function mutations in the RET proto-oncogene, encoding a receptor tyrosine kinase (Takahashi and Cooper, 1987) , cause the inherited multiple endocrine neoplasia type 2 (MEN 2) syndromes, MEN 2A, MEN 2B and familial MTC (Carlson et al., 1994; Donis-Keller et al., 1993; Eng et al., 1994 Eng et al., , 1996a Hofstra et al., 1994; Mulligan et al., 1993) . As of 1996, germline RET mutations have been described in 92% of all MTC with a hereditary background (Eng et al., 1996a) . Further work in the intervening 4 years suggest that495% of all MEN 2 have demonstrable germline RET mutations. In contrast, little is known about the etiology of the majority (75%) of all MTC, which are sporadic. Depending on the method used and perhaps the region of origin, somatic RET mutations, predominantly M918T, are found in about 30 ± 70% of sporadic MTC . However, mutation analysis in subpopulations of sporadic MTC showed that these somatic mutations are heterogeneously present (Eng et al., 1996b) . It was, therefore, postulated that they might occur during tumor evolution rather than being the initiating step. A rare sequence variant in exon 14 (S836S) has been found to be over-represented in patients with sporadic MTC when compared to geographically matched control groups (Ceccherini et al., 1999; Gimm et al., 1999c ). The precise mechanism remains to be elucidated.
Physiologic RET activation requires binding with ligand and co-receptor. One of four related ligands, GDNF, NTN, PSP, and ART, needs to interact with one of four glycosyl-phosphoinositol (GPI)-linked coreceptors, GFRa-1, GFRa-2, GFRa-3 and GFRa-4, before the heterotetrameric complex can bind RET Durbec et al., 1996; Enokido et al., 1998; Jing et al., 1996 Jing et al., , 1997 Kotzbauer et al., 1996; Milbrandt et al., 1998; Thompson et al., 1998; Trupp et al., 1996) . Recently, another ligand, Enovin (EVN), was described but EVN is identical to ART (Masure et al., 1999) . While each ligand preferentially binds to one co-receptor, low anity interactions with other coreceptors has also been noted for some ligands in vitro Enokido et al., 1998; Jing et al., 1997; Klein et al., 1997; Milbrandt et al., 1998; Sanicola et al., 1997; Trupp et al., 1998) . Activation of RET in this manner plays a signi®cant role during human development (Sanchez et al., 1996; Schuchardt et al., 1994) but may also be important during adulthood (Masure et al., 1999) . There is also growing evidence that RET, each of the ligands and each of the co-receptors are dierentially expressed in a tissuespeci®c and time-speci®c manner (Airaksinen et al., 1999; Baloh et al., 2000; Jing et al., 1997; Masure et al., 1999; Naveilhan et al., 1998; Sanicola et al., 1997) .
If gain-of-function RET mutations are associated with human MTC, then it is equally plausible that mutations in the gene encoding one of the human coreceptor homologues, GFRa-1, GFRa-2 or GFRa-3, could play a role in the pathogenesis of MTC. Hence, we sought to examine the presence of high penetrance somatic mutations or low penetrance germline variants in the genes encoding the three human co-receptors in sporadic MTC.
Results

Mutation analysis of GFRA1, GFRA2 and GFRA3
Mutation analysis of all coding exons and¯anking intronic sequences of GFRA1, GFRA2 and GFRA3 of genomic DNA from 31 sporadic MTC tumors revealed six variants in GFRA1, one variant in GFRA2 and two variants in GFRA3 (Table 3 ; Figure 1 ). Corresponding germline DNA was examined for the presence of each of these variants, and all were also present in the germline. The frequencies of two variants in GFRA1 diered signi®cantly from those in a race-matched control group (Table 1) . The variant c.537C4T (N179N; exon 4) was under-represented in sporadic MTC when compared to the normal controls (P50.05). We analysed whether this sequence variant correlates with the presence of an alternatively spliced exon between exon 3 and exon 4 (Myers et al., 1999) but did not con®rm this hypothesis (data not shown). The other sequence variant (7193C4G) lies in the 5'UTR likely at or near to the transcriptional start site. This sequence variant is normally very rare (Myers et al., 1999) and was not found among 62 race-matched control alleles in this study. In contrast, among 62 MTC alleles, nine carried the polymorphic G allele at nucleotide 7193. Thus, this G variant was heterozygously present in three patients and homozygously present in another three patients with sporadic MTC (Table 2, P50.05).
GFRA1 expression analyses
Because we felt that the C/G variation at 7193 might aect transcription, we performed semi-quantitative duplex PCR comparing GFRA1 to the housekeeping gene GPI to analyse whether any correlation exists between GFRA1 mRNA levels and the sequence at position 7193 (Figure 2 ). GFRA1 expression at the mRNA level was seen in all 10 tumors that had RNA available. Interestingly, the heterozygous presence of the rare sequence variant 7193C4G seemed to be an associative trend with higher GFRA1 transcript levels (P=0.06). Unfortunately, no cDNA was available from those three patients with homozygous 7193G/ G variant.
We then analysed the expression of GFRa-1 at the protein level by immunohistochemistry (Table 2, Gimm et al., 1999a; Myers et al., 1999; Onochie et al., 2000) . n.r., not reported; n.s., not signi®cant; MTC, medullary thyroid carcinoma a GFRA1 compared to GPI mRNA levels (see also Figure 3 ). Results have been published (S836S is germline, M918T is somatic) (Gimm et al., 1999c) Oncogene Over-representation of GFRa-1 variant with sporadic MTC O Gimm et al Figure 3 ). Overall, in agreement with the GFRA1 mRNA levels, at least weak expression of GFRa-1 protein was noted in all tumors. Generally, cytoplasmic staining was weak to moderate while nuclear staining varied from weak to strong (Table 2) . Interestingly, tumors from all three patients with homozygous 7193G/G showed strong nuclear staining intensity while cytoplasmic staining intensity was weak to moderate (Figure 3a ± c). The histopathologic appearance of these three tumors was remarkable in that there were many apoptotic cells present, perhaps indicating a fast-growing tumor. The three tumors with heterozygous 7193C/G showed moderate cytoplasmic staining intensity (Figure 3d ± f). Apoptotic cells were only seen occasionally. In contrast, most tumors with the wild-type 7193C/C showed rather weak GFRa-1 staining (Figure 3g ± i) . However, there were a few exceptions (Table 2) , i.e. tumors wild-type at position 7193 (C/C) and moderate or strong cytoplasmic and/or nuclear staining (Figure 3k ± m) . Apoptotic cells were rarely observed among tumors with the wild-type 7193C/C.
GFRa-1 expression was not associated with the presence of any of the other polymorphic sequence variants in GFRA1, GFRA2, and GFRA3 (data not shown). As shown in Table 2 , GFRA1 expression neither correlated with the presence of the somatic M918T mutation nor the germline S836S sequence variant. However, among the 25 tumors wild-type at position 7193 in GFRA1, two tumors (Patient #6 and #18, Table 2 and Figure 3l ) showed strong cytoplasmic and three others (Patient #10, #17, #20) strong nuclear staining intensity for GFRa-1, patterns normally seen in the presence of the 7193 variant. All these ®ve tumors harbored the wild-type sequence at codons 836 and 918 of RET. In contrast, the status at codons 836 and 918 were random among the six cases with either 7193G/G or 7193C/G.
Discussion
In this study, we have demonstrated absence of somatic mutations in GFRA1, GFRA2 and GFRA3 in a series of sporadic MTC, but we have found two germline sequence variants in GFRA1 which diered in frequency between sporadic MTC cases and matched normal controls. One variant c.573T4C was located in exon 4 and under-represented in sporadic MTC cases, as compared to controls. Interestingly, the frequency of this variant in our control group (55%) was higher than the frequency reported in the literature (40 ± 46%), although the values from the literature were derived from a Canadian control group as well as from Germans with brain tumors. Thus, in this Germanbased case-control comparison, the dierence in variant frequency between the MTC (35%) and controls (55%) is signi®cant (P50.05). Why underrepresentation of this polymorphic allele, which does not alter the amino acid and does not alter splicing, is associated with sporadic MTC is unclear, although linkage disequilibrium with other loci is a plausible explanation.
Even more striking was the over-representation of a rare sequence variant at position 7193 in GFRA1 in sporadic MTC, especially since three patients were homozygous for this sequence variant and we did not ®nd this variant in any of 62 control alleles. The dierence was signi®cant, whether we compared genotypes or alleles. Of note, the 7193C4G variant Figure 2 Ethidium-bromide stained agaros gel of duplex RT ± PCR products. GFRA1 and a housekeeping gene, GPI, were coampli®ed from DNA extracted from each of 10 sporadic MTC. GFRA1 mRNA levels were higher (mean 0.7025) in cases with the 7193C/G sequence variant versus those with wild-type 7193C/C (mean 0.4869) when compared to the housekeeping gene GPI (P=0.065, one-tailed t-test); *NA, see Table 2 Over-representation of GFRa-1 variant with sporadic MTC O Gimm et al was always either heterozygously or homozygously present in both germline and tumor DNA. Hence, it is unlikely that GFRA1 functions as a tumor suppressor gene in this situation; further, LOH on 10q26 has not been reported in MTC. Because the presence or absence of the GFRA1 7193 variant was randomly associated with the presence or absence of the RET S836S variant and the presence or absence of somatic RET M918T, it suggests that the 7193 variant might be a low penetrance allele, independent of RET, associated with sporadic MTC risk. Because 7193 lies in the 5'UTR, likely at or around the transcriptional start site, and perhaps even within the promoter, a variation in that region associated with sporadic MTC risk is interesting and might suggest the mechanism of the association. In agreement with our hypothesis, overall, we observed that the presence of the sequence variant 7193C4G was associated with higher GFRA1 transcript levels. Immunohistochemistry further supported this impression. By immunohistochemistry, it would appear that either the heterozygous or homozygous presence of the polymorphic G allele was associated with increased expression compared to tumors that are wild-type at 7193, although the former had predominant cytoplasmic expression and the latter nuclear. Of interest, tumors with the homozygous sequence variant (7193G/G) showed strong GFRa-1 immunoreactivity accompanied by increased numbers of apoptotic cells, which is usually associated with rapidly growing tumors. Our data also suggest that the 7193 variant status alone is not the only modulator of high GFRa-1 expression as a few tumors without the G variant were found to express GFRa-1 as well: other mechanisms must exist that in¯uence the level of GFRA1 transcription and subsequent translation in sporadic MTC.
The functional meaning of the overall higher levels of GFRa-1 associated with the presence of the 7193G allele is not obvious. It is conceivable that, in the presence of appropriate ligands (e.g. GDNF, NTN), higher levels of GFRa-1 may lead to increased interaction with and subsequent activation of RET. Because GFRa-1 not only interacts with its major ligand GDNF but it can also interact with lower anity with NTN and ART Jing et al., 1997) , it is possible that increased GFRa-1 expression could mean further activation of RET via ligands other than GDNF. GFRa-1, like many GPI-linked membrane-bound proteins, form into complexes around lipid rafts at the membrane and has recently been shown to recruit RET to these lipid rafts after GDNF binding, followed by increased RET phosphorylation and increased Src-RET interaction. Increased GFRa-1 expression in the presence of the GFRA1 7193 variant would be predicted to lead to increased numbers of such complexes at the lipid rafts and hence, increased recruitment of RET to them with subsequent increased signaling. Although controversial, it has been described that GFRa-1 can signal down a pathway independent of RET and its ligands (Trupp et al., 1998) . Thus, increased levels of this co-receptor would increase signaling down this other pathway as well. All these postulates do not contradict our observation of increased apoptotic cells associated with more rapidly growing tumors in the individuals with the G/G genotype at position 7193.
Despite the location of 7193 in the 5'UTR/ promoter region with all its functional implications, it is also equally plausible that the variant 7193C4G may be in linkage disequilibrium with another locus which directly contributes to low penetrance susceptibility to sporadic MTC; such a locus would most likely lie upstream of GFRA1. In summary, mutation analysis of GFRA1, GFRA2 and GFRA3 revealed overrepresentation of an upstream variant in GFRA1 7193C4G as well as under-representation of GFRA1 variant c.573T4C in sporadic MTC cases compared to matched controls. The GFRA1 7193 variant might lend low level susceptibility to sporadic MTC by a mechanism related to increased expression, as suggested by our data. However, the precise mechanisms for both these variants and how they can act as low penetrance susceptibility loci for the development of sporadic MTC remains to be elucidated. To date, therefore, we have shown that both RET and GFRA1 and/or loci in proximity to them might represent low penetrance susceptibility genes for sporadic MTC with relative risks ranging from 2 to 7 (Gimm et al., 1999c and this study).
Materials and methods
Patients and specimens
A series of 31 German patients diagnosed with sporadic MTC was accrued after informed consent was given. Patients were classi®ed as having sporadic MTC when no germline mutations could be identi®ed in the RET proto-oncogene (Gimm et al., 1999c) . In addition, there was no family history of MTC, pheochromocytoma or parathyroid disease. At operation, tumor tissue and corresponding peripheral blood samples were obtained from each patient. A piece of the tumor, which macroscopically appeared to be free of normal tissue, was excised and¯ash frozen in liquid nitrogen for all patients. The remaining tissue was ®xed by immersion in 10% buered formalin for histopathological analysis.
Peripheral blood was obtained from a race-matched control group, with their informed consent. This control group consisted of patients who were admitted to the Department of General Surgery, Halle, Germany, for nonthyroid-related diseases.
DNA extraction
Genomic DNA from¯ash frozen tissue and peripheral blood leucocytes was extracted using the QIAamp Tissue Kit (Qiagen, Santa Clarita, CA, USA) according to the manufacturer's instructions.
Genomic structure and intron-exon boundaries in GFRA2
The genomic structure of GFRA1 and GFRA3 including the intron-exon boundaries have been previously described (Angrist et al., 1998; Myers et al., 1999; Onochie et al., 2000) . The genomic structure of GFRA2 had to be determined and is described in detail elsewhere (Mulligan et al., in preparation) .
PCR-based mutation analysis
Primers and PCR conditions used to amplify exons of GFRA1 have been previously described (Gimm et al., 1999a) . Primers to generate amplicons of GFRA2 were designed according to the sequences obtained from long range and Vectorette PCR (Table 3 ). The human GFRA3 locus has recently been described (Onochie et al., 2000) and primers to generate amplicons of GFRA3 were designed accordingly (Table 3) . PCR ampli®cation was carried out in 16 PCR buer (Qiagen) containing 1.5 mM MgC1 2 , 200 mmol/l dNTP, 0.6 mmol/l of both sense and antisense primer, 2.5 U Taq
Over-representation of GFRa-1 variant with sporadic MTC O Gimm et al polymerase (Qiagen), and 100 ± 200 ng or tumor DNA template in a 50 ml volume. PCR conditions were: one cycle of 15 min at 958C, 35 cycles of 1 min at 958C, 1 min at 58-628C (Table 3) , and 1 min at 728C, followed by one cycle of 10 min at 728C. Mutation analysis was performed using a combination of single-strand conformational polymorphism analysis (SSCP) and direct sequencing (Table 4) . For each exon, at least three randomly chosen samples were sequenced to exclude the possibility that sequence variants were missed by SSCP. No optimal SSCP conditions were found for exon 1 of GFRA1 and GFRA2. Instead, mutation analysis was performed by direct sequencing.
Before SSCP, some PCR products (Table 4) were subjected to further digestion to obtain smaller fragments that are believed to be more likely to reveal variant patterns using SSCP (Jordanova et al., 1997) . Two microliters of the resulting PCR/digestion product were added to 3 ml of formamide buer, then heated to 958C for 10 min, and subsequently cooled on ice. The samples were subjected to electrophoresis through polyacrylamide/Tris-Borate-EDTA gels (Table 4) . Subsequent silver staining was done as previously described (Gimm et al., 1999b) . If SSCP revealed a dierent banding pattern, the remaining PCR aliquot was subjected to puri®cation and semi-automated sequencing as described (Gimm et al., 1997) .
RNA extraction and expression analysis of GFRA1
To analyse whether the presence of the rare sequence variant 7193C4G in¯uences expression of GFRA1 at the mRNA level, we extracted RNA from 10 tumors using TRIzol reagent (Life Technologies, Rockville, MD, USA) according to the manufacturer's instructions. RT ± PCR was performed using the 1st Strand cDNA Synthesis Kit (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions. To determine the expression level of GFRA1 at the mRNA level, 1 m1 cDNA was used in a duplex PCR containing 1.2 mmol/l each of intron-spanning GFRA1 primers (5'-GA-TATATTCCGGGTGGTCCC-3'; 5'-AAACAGTTGGGCT-TCTCCCT-3') and 0.2 mmol/l each of primers for the housekeeping gene glucosyl-phosphatidylinositol (GPI) (5'- Ra2-I-4F 5'-GCCTCTGACCTGCTCTCTTG-3' 489 60 Ra2-I-4R
5'-GGTCATAATTCGATGCACCC-3' 5
Ra2-I-5F 5'-CCCCTGTTTTCTCTATTGCG-3' 170 58 Ra2-I-5R
5'-CAGGTGAGCAGGAAGAGCTTA-3' 6
Ra2-I-6F 5'-CCGTACCTCTCTCCTCTCCC-3' 205 58 Ra2-I-6R
5'-TTGGGGAGAACATCCAGAAC-3' 7
Ra2-I-7F 5'-ACTTCTCTGCATCGTCCCTC-3' 272 58 Ra2-I-7R
5'-GAGTCATTTCCCATGCCACT-3' 8
Ra2-I-8F 5'-GCTGAGGGTGTCAGAGAAGG-3' 243 58 Ra2-E-8R
5'-CTCTGTGAAGCACATGCTTAAC-3' 9
Ra2-E-9F 5'-CTCACGACAAATATCATCCC-3' 127 58 Ra2-1434R
5'-CAGCCTACAAGGCCTGTTTC-3'
Ra3-E-2F 5'-GAGACCCCCTTCCCACAGA-3' 378 60 Ra3-I-2Rb GACCCCCAGTTCCAGAAGCTGC-3'; 5'-GCATCACGT-CCTCCGTCACC-3'). PCR conditions were: one cycle of 15 min at 958C, 30 cycles of 45 s at 958C, 30 s at 588C, 15 s at 728C, followed by one cycle of 10 min at 728C. The PCR product was then subjected to electrophoresis through a 2% agarose gel and visualized by UV transillumination after ethidium bromide staining. The intensity of the PCR products was measured using ImageQuant (Molecular Dynamics, Sunnyvale, CA, USA).
GFRa-1 immunohistochemistry
To analyse the expression of GFRa-1 at the protein level, we performed immunohistochemistry. Four-micron sections of paran-embedded, formalin-®xed tissue were cut, mounted on Superfrost plus slides and baked for 2 h at 608C.
Immunostaining was performed as previously described (Gimm et al., 2000) except using a primary goat polyclonal antibody raised against GFRa-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The speci®city of this antibody has been previously reported. In brief, sections were deparanized and rehydrated by passing through xylene and a graded series of ethanol solutions. Antigen retrieval was performed by boiling at 988C in 0.01 M sodium citrate buer pH 6.4 in a microwave oven for 20 min. In order to block endogenous peroxidase activity, the sections were incubated with 1% hydrogen peroxide in PBS for 30 min after cooling to room temperature. After blocking for 30 min in 0.75% horse serum, the sections were incubated overnight at 48C with a primary goat polyclonal antibody against GFRa-1 (Santa Cruz Biotechnology) at a dilution of 1 : 200. Primary antibody binding was localized by using an avidin-biotinperoxidase kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instruction. The chromogenic reaction was carried out with 0.05% 3,3' diaminobenzidine (Sigma, St. Louis, MO, USA) using nickel cobalt ampli®cation, which gives a black product. Following counterstaining with Nuclear Fast Red (Rowley Biochemical Institute, Danvers, MA, USA) and mounting, the slides were evaluated under a light microscope. Intensity of staining was classi®ed separately for the nucleus and the cytoplasm and graded strong (+++), moderate (++), weak (+) or absent (7).
RET sequence variants and GFRa-1 expression Germline S836S and somatic M918T sequence variants have been found to be associated with MTC. Since the sequence status at those positions in the MTCs analysed here was known (Gimm et al., 1999c) , we analysed by inspection whether they correlated with expression levels of GFRa-1. 
